- Leading AstraZeneca (AZN) shareholders aren't happy about the company's rebuffing of Pfizer's latest £69B ($117B) offer.
- Jupiter Fund Management, a top-30 shareholder in the U.K. pharmaceuticals provider, is "disappointed" that the rejection was so categorical. "They should have at least engaged in a constructive conversation...to assess the opportunities that a combined entity could bring," Jupiter says.
- A fund manager at a top 10 investor says: "We do not think the Astra management have done a good job on behalf of shareholders."
- AstraZeneca's shares are -12% premarket.
- Previous coverage